

Frankie Ann Holmes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1611865/publications.pdf>

Version: 2024-02-01

14
papers

133
citations

1937685

4
h-index

1474206

9
g-index

14
all docs

14
docs citations

14
times ranked

260
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P2-13-21: Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial. <i>Cancer Research</i> , 2022, 82, P2-13-21-P2-13-21.	0.9	1
2	Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 807-818.	7.0	34
3	Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial. <i>Cancer Research</i> , 2021, 81, PD3-03-PD3-03.	0.9	2
4	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6149-6157.	7.0	29
5	Leptomeningeal metastatic hormone receptor positive, HER2 and PD-L1 negative, breast cancer responds after pembrolizumab added to abemaciclib: A case study. <i>Current Problems in Cancer Case Reports</i> , 2020, 2, 100033.	0.1	1
6	Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients. <i>Npj Breast Cancer</i> , 2019, 5, 36.	5.2	9
7	Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in T1/T2/T3/T4/T5/T6/T7/T8/T9/T10/T11/T12/T13/T14/T15/T16/T17/T18/T19/T20/T21/T22/T23/T24/T25/T26/T27/T28/T29/T30/T31/T32/T33/T34/T35/T36/T37/T38/T39/T40/T41/T42/T43/T44/T45/T46/T47/T48/T49/T50/T51/T52/T53/T54/T55/T56/T57/T58/T59/T60/T61/T62/T63/T64/T65/T66/T67/T68/T69/T70/T71/T72/T73/T74/T75/T76/T77/T78/T79/T80/T81/T82/T83/T84/T85/T86/T87/T88/T89/T90/T91/T92/T93/T94/T95/T96/T97/T98/T99/T100) in T1/T2/T3/T4/T5/T6/T7/T8/T9/T10/T11/T12/T13/T14/T15/T16/T17/T18/T19/T20/T21/T22/T23/T24/T25/T26/T27/T28/T29/T30/T31/T32/T33/T34/T35/T36/T37/T38/T39/T40/T41/T42/T43/T44/T45/T46/T47/T48/T49/T50/T51/T52/T53/T54/T55/T56/T57/T58/T59/T60/T61/T62/T63/T64/T65/T66/T67/T68/T69/T70/T71/T72/T73/T74/T75/T76/T77/T78/T79/T80/T81/T82/T83/T84/T85/T86/T87/T88/T89/T90/T91/T92/T93/T94/T95/T96/T97/T98/T99/T100 cancer. <i>Cancer Medicine</i> , 2018, 7, 2288-2298.	0.784314	2
8	Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS10144-TPS10144.	1.6	0
9	Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. <i>Clinical Cancer Research</i> , 2015, 21, 4305-4311.	7.0	51
10	HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 621-621.	1.6	0
11	Scalp cooling alopecia prevention trial (SCALP).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9660-TPS9660.	1.6	0
12	Evidence of <i>PIK3CA</i> and <i>TP53</i> co-mutation in breast cancer identification on next-generation sequencing (NGS) of <i>ERBB2</i> (<i>HER2</i>)-amplified residual disease following preoperative anti-HER2 therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 625-625.	1.6	0
13	Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1017-1017.	1.6	3
14	Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses.. <i>Journal of Clinical Oncology</i> , 2012, 30, 547-547.	1.6	1